Clinical trials
Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 4,858 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06970353RecruitingPhase 2
Study of tunlametinib for NRAS-mutant advanced thyroid cancer
This trial tests a targeted drug (tunlametinib) for advanced thyroid cancer that has a specific genetic change called NRAS mutation. It may help people whose cancer is not responding to standard treatments like radioactive iodine.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06979908RecruitingPhase 2
A study of fruquintinib plus immunotherapy for advanced colorectal cancer
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and chidamide) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Changchun, JilinAges 18–75 - NCT06992648RecruitingPhase 3
Two drug combos for advanced colorectal cancer
This trial tests a two-drug combination (trifluridine/tipiracil plus regorafenib) against a standard pair (trifluridine/tipiracil plus bevacizumab) for people with advanced colorectal cancer that has stopped responding to prior treatments. It aims to find which combination works better.
Hangzhou, ZhejiangAges 18 years+ - NCT06992739RecruitingPhase 2
Trilaciclib with chemotherapy for EGFR-mutant advanced lung cancer
This study tests whether adding trilaciclib to a new chemotherapy (sacituzumab tirumotecan) can help people with EGFR-mutant lung cancer that keeps growing after certain targeted treatments. The goal is to see if it slows the cancer and reduces side effects.
Xiamen, FujianAges 18–75 - NCT06994377Recruiting
Emotional distress study for newly treated metastatic breast cancer
This trial studies emotional distress in people with metastatic breast cancer who have not yet received treatment for their advanced disease. It explores how different standard first-line therapies affect emotional well-being.
AnconaAges 18 years+ - NCT07001618RecruitingPhase 2
Fecal transplant with immunotherapy for advanced lung cancer
This trial tests whether taking an oral fecal transplant (MaaT033) along with the immunotherapy drug cemiplimab can help people whose lung cancer stopped responding after antibiotics. It's for people with advanced non-small cell lung cancer whose cancer got worse after standard immunotherapy.
DijonAges 18 years+ - NCT07006077RecruitingPhase 2
Investigational virus injection for advanced pancreatic cancer
This trial tests a new treatment that uses a virus to attack tumor cells directly. It is for people with advanced pancreatic cancer that has not responded to standard therapy. The virus is injected into a tumor, and the goal is to see if it can shrink the cancer or slow its growth.
Hangzhou, ZhejiangAges 18–75 - NCT07011654RecruitingPhase 1/Phase 2
Study of two drugs for metastatic triple-negative breast cancer
This trial tests a combination of two drugs, naxitamab and sacituzumab govitecan, for people with metastatic triple-negative breast cancer that has already been treated with at least one chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Houston, TexasAges 18 years+ - NCT07018661RecruitingPhase 2/Phase 3
Testing a PET/CT scan for advanced stomach cancer
This trial tests whether a special PET/CT scan (using a drug called [18F]F-FAPI) and a laparoscopy (a small camera through the belly) can better show the spread of advanced stomach or esophagus cancer before surgery. The goal is to help doctors decide the best treatment plan.
AlmeloAges 18 years+ - NCT07020065RecruitingPhase 2
Reduced chemo plus immunotherapy vs immunotherapy alone for older lung cancer patients
This trial tests whether a reduced dose of chemotherapy plus an immunotherapy drug (Cemiplimab) works better than Cemiplimab alone for older or frail patients with advanced lung cancer whose PD-L1 level is below 50%. It aims to find a gentler but effective treatment option.
Fribourg, Villars-sur-GlâneAges 70 years+ - NCT07032584Recruiting
Tele-rehab for rural men with metastatic prostate cancer
This trial tests a home-based exercise and support program delivered by phone or video for men with metastatic prostate cancer living in rural areas. The goal is to see if this approach improves quality of life and physical function compared to standard care.
Salt Lake City, UtahAges 21 years+ - NCT07037199RecruitingPhase 2
A new drug combo for HR+ advanced breast cancer
This trial tests a sequence of three drugs: first trastuzumab rezetecan (a targeted therapy), then a CDK4/6 inhibitor plus hormone therapy. It's for people with a type of breast cancer called HR-positive, HER2-low or ultra-low that has spread or come back and has already progressed on a CDK4/6 inhibitor and hormone therapy.
Guangzhou, GuangdongAges 18 years+ - NCT07042919RecruitingPhase 1/Phase 2
Zanzalintinib for advanced liver cancer after prior treatment
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
Chicago, IllinoisAges 18 years+ - NCT07050394RecruitingEarly Phase 1
Experimental drug for advanced colorectal cancer
This trial tests a new experimental drug (HNF4α srRNA) given through a vein for people with advanced colorectal cancer that has not responded to or cannot be treated with standard therapies. The goal is to see if this treatment can help shrink or slow the growth of the cancer.
Shanghai, None SelectedAges 18 years+ - NCT07055399RecruitingPhase 2
Neoadjuvant immunotherapy with two drugs plus chemo for cervical cancer
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy before surgery for locally advanced cervical cancer. It aims to shrink tumors and improve outcomes for patients who haven't had prior systemic treatment.
Fuzhou, FujianAges 18–70 - NCT07068542Recruiting
New drug combo for advanced thyroid cancer
This trial tests a new drug called sacituzumab tirumotecan combined with immunotherapy for people with advanced thyroid cancer that cannot be removed by surgery or has spread. It aims to see if this combination can help shrink tumors or slow down the cancer.
Hangzhou, ZhejiangAges 18 years+ - NCT07069842Recruiting
Gastric cancer immunotherapy prediction model
This study looks at markers in your tumor to predict how well immunotherapy might work for you. It aims to create a model that helps doctors choose the best treatment for advanced gastric cancer.
Changzhi, ShanxiAges 18–75 - NCT07081555RecruitingPhase 1
Testing a new radioactive drug for HER2-positive advanced breast cancer
This trial tests a new radioactive drug, [177Lu]Lu-ABY-271, to see how safe it is and where it goes in the body. It is for people with HER2-positive breast cancer that has spread and cannot be removed by surgery.
GothenburgAges 18 years+ - NCT07096258Recruiting
Blood test to guide first treatment for advanced lung cancer
This trial is for people with advanced non-small cell lung cancer (NSCLC) who have not yet started treatment. It studies a simple blood test that checks for genetic changes in the cancer, to help doctors choose the most effective first treatment.
Nancy, LorraineAges 18 years+ - NCT07100600RecruitingPhase 2
Targeted drug with or without radiation for HER2-positive breast cancer brain tumors
This trial tests whether adding radiation therapy to a targeted cancer drug (trastuzumab rezetecan) is better than the drug alone for women with HER2-positive breast cancer that has spread to the brain. If you have untreated brain tumors from this type of breast cancer, this study aims to find the best way to stop them from growing.
Zhengzhou, HenanAges 18 years+ - NCT07124858Recruiting
Fruquintinib for advanced colorectal cancer
This study tracks how well fruquintinib works for people with advanced colorectal cancer that has spread. It aims to find factors that predict better outcomes, using blood and tumor samples.
Poitiers, FranceAges 18 years+ - NCT07132307Recruiting
Mouthpiece help after failed sleep apnea nerve stimulator
This study tests whether adding a special mouthpiece (mandibular advancement device) can help people whose sleep apnea wasn't fully treated by a nerve stimulator implant. You would use the mouthpiece at night and take home sleep tests to see if your breathing improves.
St Louis, MissouriAges 18–70 - NCT07134881Recruiting
Navigating serious illness with digital care planning
This trial tests a digital tool to help people with serious illnesses and their caregivers plan future medical care. It may help you discuss your goals and treatments with your doctor and family.
SingaporeAges 21 years+ - NCT07143045Recruiting
Zorifertinib for lung cancer that has spread to the brain
This trial tracks how well zorifertinib works as a first treatment for people with a specific type of advanced lung cancer that has spread to the brain or spinal cord lining. Participants may receive zorifertinib or another standard treatment, and researchers will monitor their response over time.
Hefei, AnhuiAges 18 years+
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 4,858 recruiting advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
- Recurrent or Metastatic Solid Tumors
- Advanced Solid Tumor
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.